The Andrew Hill Investment Fund has expressed optimism about Vertex Pharmaceuticals' future growth.
The Andrew Hill Investment Fund has signaled positive expectations for Vertex Pharmaceuticals Inc (VRTX) in its recent communications. This outlook comes as the company prepares to announce its third-quarter financial results on November 2nd. Vertex's stock closed at US$509.72, reflecting a decline of 0.47% for the day and a decrease of 4.85% over the past month, despite a year-to-date increase of 11.31%.
Investor takeaway: Investors will be watching closely as Vertex approaches its earnings release, particularly in light of the fund's optimistic growth outlook.
Advertisement
Vertex Pharmaceuticals Inc
VRTX.US
VRTX.US
Vertex Pharmaceuticals Inc
WealthAwesomeMarket cap
$128.16B
P/E
29.4x
52W high
$560.25
52W low
$402.58
1W change
-0.69%
Beta
0.28
Analyst Price Targets
Based on 32 analysts covering VRTX · as of Oct 5, 2026
Wall Street analysts forecast VRTX stock price to rise 13.5% over the next 12 months.
Consensus
Buy4.34 / 5.00
Avg. Target
C$571.39
+13.5% Upside
Current Price
C$503.25
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VRTX's historical volatility
30-Day Vol
18.5%
Annualized
90-Day Vol
27.4%
Annualized
Trend (90d)
+22.4%
Annualized drift
90d Mean
C$545.22
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$516.87 | C$484.88 – C$550.97 |
| 60 trading days | C$530.86 | C$484.99 – C$581.06 |
| 90 trading days | C$545.22 | C$488.10 – C$609.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Vertex Shares Close at $509.72 with Increased Trading Volume
Vertex Pharmaceuticals' last closing price was $509.72, with a trading volume of 372,654 shares, significantly higher than its 20-day average of 990,155 shares.
Bull case
The confidence from the Andrew Hill Investment Fund suggests that Vertex may perform strongly in the future. The company has solid profit margins and a good return on equity, which supports this positive outlook.
Bear case
However, the recent stock performance shows a slight decline over the past few weeks. This may raise concerns among investors, even with the optimistic outlook from the fund.
Andrew Hill Investment Fund's Positive Growth Outlook
Advertisement
The Andrew Hill Investment Fund has released a statement expressing its belief in Vertex Pharmaceuticals' potential for significant growth. This positive sentiment is particularly noteworthy as Vertex prepares to announce its third-quarter financial results on November 2nd. With a market capitalization of approximately US$128.16 billion and a P/E ratio of 29.449, Vertex has shown strong fundamentals. Its profit margin stands at an impressive 35%, highlighting the company's ability to convert revenue into profit.
Recent Stock Performance and Trading Volume
Vertex Pharmaceuticals' stock closed at US$509.72, marking a decline of 0.47% for the day and reflecting a 1.8% decrease compared to its 50-day moving average of US$519.19. Over the past month, the stock has decreased by 4.85%, although it has increased by 11.31% year-to-date. The trading volume was notably high at 372,654 shares, which is 1.50 times its 20-day average of 990,155 shares, suggesting increased investor interest following the fund's announcement.
What to Watch Ahead of Q3 Earnings Release
Investors should prepare for Vertex's third-quarter financial results scheduled for November 2nd. The strong outlook from the Andrew Hill Investment Fund may influence market reactions, particularly as analysts have set an average price target of US$571.39 for the stock. This target represents an implied upside of 12.1% from the last close. Additionally, Vertex's stock is currently trading within 68% of its 52-week range of US$402.58 to US$560.25, indicating potential volatility ahead.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
